University of Colorado Cancer Center


 

Brain Mets & CNS Coverage of MET Signaling in NSCLC: Alectinib vs. Crizotinib, Unmet Need in ROS1, TKI Resistance

96 views
June 11, 2021
Comments 0
Login to view comments. Click here to Login